Amplifold: Closing the Sensitivity Gap in Rapid Diagnostics

Rapid diagnostics have become a cornerstone of modern healthcare — accessible, fast, and scalable. Yet their limitations remain clear: when sensitivity drops, so does reliability, especially in early-stage detection. Amplifold addresses this challenge by rethinking how signals are generated — not how tests are used.

1 Min.

The company applies DNA origami nanostructures to amplify detection signals in lateral flow assays. Instead of introducing new devices or workflows, the approach enhances existing tests, making them significantly more sensitive while preserving their simplicity.

This “upgrade rather than replace” logic is central to how Amplifold presents itself publicly. As the team notes:

“We are extending the capabilities of rapid tests into areas that previously required lab-based infrastructure.”

External coverage highlights the scale of the improvement, with sensitivity gains of up to 100x while maintaining cost efficiency and usability.

With a €5M seed round now closed, Amplifold is moving toward regulatory approval and first applications — a transition from academic breakthrough to deployable diagnostic technology. The broader implication is clear: bringing higher-quality diagnostics closer to patients, without adding complexity.

amplifold team sitting on stairs